Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469885 · ClinicalTrials.gov registry record · Phase 2
Reduction of Smoking in Cardiac Disease Patients
A Phase 2 study of Cardiovascular Disease and Tobacco Use Disorder, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
- 2
- Study locations
NCT00469885: Completed Phase 2 study of Cardiovascular Disease and Tobacco Use Disorder, sponsored by National Institute on Drug Abuse (NIDA).
NCT00469885 is a Phase 2 study of Cardiovascular Disease and Tobacco Use Disorder that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 152 participants, below the 2,696-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00469885, a Phase 2 study of Cardiovascular Disease and Tobacco Use Disorder, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluates the effect of smoking reduction vs usual care (quitting advice only) for individuals with peripheral arterial disease who smoke.
Conditions Studied
Interventions
- DRUG Nicotine replacement
- BEHAVIORAL Motivational counseling
Study Locations (2)
Minnesota
- Univeristy of Minnesota - Minneapolis
- Univerisity of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2001-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00469885 record still lists
NCT00469885 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 2,696-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Nicotine replacement is the first listed.
NCT00469885 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00469885 about?
NCT00469885 is a clinical study titled "Reduction of Smoking in Cardiac Disease Patients". This study evaluates the effect of smoking reduction vs usual care (quitting advice only) for individuals with peripheral arterial disease who smoke.
What is the current status of trial NCT00469885?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2001-01. Estimated completion is 2005-12.
What conditions does trial NCT00469885 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Tobacco Use Disorder.
What interventions are being tested in trial NCT00469885?
The interventions under investigation include: Nicotine replacement (DRUG), Motivational counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT00469885?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00469885 being conducted?
This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00469885's enrollment target sits among peer trials
152 60th of 137 higher than 78 of 137 other Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
Metformin in Kidney Disease
COMPLETED · Phase 2
-
Biomarker Guided Therapies in Stage A/B Heart Failure
COMPLETED · Phase 2
-
The Fibrin Pad Cardiovascular Study
COMPLETED · Phase 2
-
Trial of Oral Glutamine on Mitochondrial Function in CKD
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia